22KIT
and freedom than traditional systems.
All pump and CGM data can be easily shared with
either an unlimited number of family or carers using the
Medtrum EasyFollow app, or with your healthcare team
for remote support via Medtrum's EasyView reports.
TouchCare Nano System is future-proofed, ready with
hybrid closed-loop functionality for Automated Insulin
Delivery. Later on this year Medtrum will introduce the
Hybrid Closed Loop (HCL) function to its TouchCare®
Nano System thanks to a customised APGO algorithm
that works together with the Nano pump and CGM to
adjust insulin delivery automatically.
www.medtrum.co.uk
OMNIPOD
Following on from last month's announcement that the
FDA in the US has gained approval for its Omnipod 5
Automated Insulin Delivery (AID) device which works with
Dexcom's CGM.
Speaking this month to MedTechDive, Omnipod's
CEO Shacey Petrovic said that one of the benefits of
the longer-than-expected timeline is now having nearly
two years' worth of performance data, which could help
adoption during the launch. Tandem Diabetes Care and
Medtronic, which currently make tubed pumps, have
both said that they will develop patch pumps to compete
alongside Omnipod.
However, Petrovic was not convinced at the
companies' ability to succeed in patch pumps due to the
complexity of the technology and market saying, "I don't
necessarily think that [competition] is a bad thing. It's a
massive, growing market with a lot of unmet need. I'm just
skeptical given what I know it requires to really do this
well. It's just not for the faint of heart."
To read the full interview, CLICK HERE.
YpsoMed's YpsoPump (right) talks to Dexcom's
CGM (left) and can be seen on the mylife (sic)
CamAPS app making a smartphone-based adaptive
automated insulin delivery AID.
YPSOMED
Swiss company YpsoMed has partnered with British startup CamDiab
Ltd to drive on smartphone-based adaptive
automated insulin delivery (AID).
CamDiab Ltd, the developer of CamAPS, an app
to manage glucose levels via insulin pumps using an
adaptive, hybrid closed-loop approach can now work with
the YpsoMed mylife insulin pump. During the first half of
2022, this easy-to-use loop solution will be launched for
the mylife YpsoPump system, starting in selected major
countries in Europe and followed by other territories
through the rest of the year.
Users can then connect the mylife YpsoPump system
to the mylife CamAPS Android mobile application and
enable the algorithm-based insulin delivery, including
bolusing from their smartphone.
The partnership with CamDiab Ltd provides a worldleading,
adaptive, hybrid closed-loop solution which
enables users of the mylife YpsoPump to better manage
their glucose levels. They can benefit from a uniquely
adapting and responsive control algorithm on their
smartphone, called 'mylife CamAPS'. The Android mobile
application is compatible with the Dexcom G6 CGM and
is the first CE-marked algorithm on a mobile app that
automatically adjusts insulin delivery on the insulin pump
based on glucose readings from the Dexcom G6 CGM.
The control algorithm has been tested extensively
in clinical trials and the results have been published in
world-leading medical journals. The app is available for
use in Europe, approved for users more than one year
and older, including pregnancy. For increased privacy
and convenience, users are able to deliver a meal-time
bolus directly from their personal smartphone should
they wish. The easy-to-use interface ensures everyday
suitability with high discretion and facilitates high
adherence - and improved therapy outcomes.